Insider and Institutional Ownership
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 7.4% of Emmaus Life Sciences shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 35.0% of Emmaus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares NeuroSense Therapeutics and Emmaus Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroSense Therapeutics | N/A | N/A | -$11.28 million | ($0.85) | -1.01 |
| Emmaus Life Sciences | $29.60 million | 0.01 | -$3.73 million | ($0.09) | -0.07 |
Emmaus Life Sciences has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| NeuroSense Therapeutics | N/A | N/A | -286.31% |
| Emmaus Life Sciences | -17.11% | N/A | -12.66% |
Volatility and Risk
NeuroSense Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 6.2, meaning that its share price is 520% more volatile than the S&P 500.
Summary
Emmaus Life Sciences beats NeuroSense Therapeutics on 8 of the 9 factors compared between the two stocks.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
